A phase 1a/b dose escalation study of the BTK/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies Meeting Abstract
| Authors: | Samaniego, F.; Sadiq, A. A.; Mahadevan, D.; Koontz, M. Z.; Villasboas, J. C.; Burke, J. M.; Reid, E. G.; Cherry, M.; Melear, J.; Priego, V.; Cobb, P.; Cull, E. H.; Conkling, P.; Cosgrove, D.; Roeker, L. E.; Haney, D. N.; Hu, J.; Sinha, R. K.; Rice, W. G.; Bejar, R. |
| Abstract Title: | A phase 1a/b dose escalation study of the BTK/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6498 |
| End Page: | 6500 |
| Language: | English |
| ACCESSION: | WOS:000893223206229 |
| DOI: | 10.1182/blood-2022-163683 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
